Galena Biopharma reverse merges with Sellas Life Sciences
Cancer immunotherapy firms Galena Biopharma Inc. and privately held Sellas Life Sciences Group Ltd. agreed to an all-stock reverse merger in which Sellas will merge into Galena and become a wholly owned subsidiary. The combined company--to be named Sellas Life Science Group Inc.--will be 67.5% owned by Sellas and 32.5% by Galena, and will take over Galena’s Nasdaq stock listing under the new symbol SLS.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.